Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Operations (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Cash from Operations readings, the most recent being 50199000.0 for Q1 2026.

  • On a quarterly basis, Cash from Operations rose 124.87% to 50199000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 165860000.0, a 276.73% increase, with the full-year FY2025 number at 137985000.0, up 437.14% from a year prior.
  • Cash from Operations hit 50199000.0 in Q1 2026 for Kiniksa Pharmaceuticals International, down from 53894000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 62053000.0 in Q3 2022 to a low of 36846000.0 in Q1 2022.
  • Median Cash from Operations over the past 5 years was 5168000.0 (2024), compared with a mean of 13704764.71.
  • Biggest five-year swings in Cash from Operations: crashed 113.16% in 2024 and later soared 1606.13% in 2025.
  • Kiniksa Pharmaceuticals International's Cash from Operations stood at 11576000.0 in 2022, then skyrocketed by 137.36% to 4325000.0 in 2023, then surged by 333.99% to 18770000.0 in 2024, then skyrocketed by 187.13% to 53894000.0 in 2025, then decreased by 6.86% to 50199000.0 in 2026.
  • The last three reported values for Cash from Operations were 50199000.0 (Q1 2026), 53894000.0 (Q4 2025), and 33677000.0 (Q3 2025) per Business Quant data.